The price-to-earnings ratio for Edwards Lifesciences Corp (NYSE: EW) is 37.78x, which is above its average ratio. Moreover, the 36-month beta value for EW is 1.09. Analysts have varying opinions on the stock, with 9 analysts rating it as a “buy,” 7 as “overweight,” 4 as “hold,” and 0 as “sell.”
The public float for EW is 591.80M and currently, short sellers hold a 1.75% of that float. On April 23, 2024, EW’s average trading volume was 4.02M shares.
EW) stock’s latest price update
Edwards Lifesciences Corp (NYSE: EW)’s stock price has gone rise by 1.19 in comparison to its previous close of 85.94, however, the company has experienced a -2.51% decrease in its stock price over the last five trading days. Zacks Investment Research reported 2024-04-22 that Besides Wall Street’s top -and-bottom-line estimates for Edwards Lifesciences (EW), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended March 2024.
EW’s Market Performance
Edwards Lifesciences Corp (EW) has experienced a -2.51% fall in stock performance for the past week, with a -8.15% drop in the past month, and a 15.70% rise in the past quarter. The volatility ratio for the week is 2.44%, and the volatility levels for the past 30 days are at 2.14% for EW. The simple moving average for the past 20 days is -5.17% for EW’s stock, with a 10.42% simple moving average for the past 200 days.
Analysts’ Opinion of EW
Wells Fargo, on the other hand, stated in their research note that they expect to see EW reach a price target of $94. The rating they have provided for EW stocks is “Overweight” according to the report published on February 02nd, 2024.
Evercore ISI gave a rating of “In-line” to EW, setting the target price at $77 in the report published on January 04th of the current year.
EW Trading at -3.31% from the 50-Day Moving Average
After a stumble in the market that brought EW to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -9.53% of loss for the given period.
Volatility was left at 2.14%, however, over the last 30 days, the volatility rate increased by 2.44%, as shares sank -7.28% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +1.35% upper at present.
During the last 5 trading sessions, EW fell by -2.51%, which changed the moving average for the period of 200-days by -3.87% in comparison to the 20-day moving average, which settled at $91.36. In addition, Edwards Lifesciences Corp saw 14.05% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at EW starting from Lippis Daniel J., who sale 857 shares at the price of $92.34 back on Apr 09 ’24. After this action, Lippis Daniel J. now owns 17,488 shares of Edwards Lifesciences Corp, valued at $79,135 using the latest closing price.
Lemercier Jean-Luc M, the CVP, EMEACLA of Edwards Lifesciences Corp, sale 14,400 shares at $92.32 during a trade that took place back on Apr 08 ’24, which means that Lemercier Jean-Luc M is holding 173,849 shares at $1,329,472 based on the most recent closing price.
Stock Fundamentals for EW
Current profitability levels for the company are sitting at:
- 0.26 for the present operating margin
- 0.77 for the gross margin
The net margin for Edwards Lifesciences Corp stands at 0.23. The total capital return value is set at 0.19. Equity return is now at value 22.52, with 15.89 for asset returns.
Based on Edwards Lifesciences Corp (EW), the company’s capital structure generated 0.09 points at debt to capital in total, while cash flow to debt ratio is standing at 1.29. The debt to equity ratio resting at 0.1. The interest coverage ratio of the stock is -150.4.
Currently, EBITDA for the company is 1.95 billion with net debt to EBITDA at -0.24. When we switch over and look at the enterprise to sales, we see a ratio of 8.63. The receivables turnover for the company is 7.18for trailing twelve months and the total asset turnover is 0.64. The liquidity ratio also appears to be rather interesting for investors as it stands at 3.38.
Conclusion
To wrap up, the performance of Edwards Lifesciences Corp (EW) has been mixed in recent times. The stock has received a bullish of “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
